Expand HELP Menu
HELP MENU

HELP Latest Press Releases

-- June 26, 2026 --

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PRNewswire 9:30 AM

-- June 25, 2026 --

Helus Pharma Announces Closing of US$50 Million Underwritten Offering Globe Newswire 9:27 AM

-- June 24, 2026 --

Helus Pharma Announces US$50 Million Underwritten Offering Globe Newswire 6:01 AM
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress Globe Newswire 6:00 AM

-- June 11, 2026 --

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference Globe Newswire 7:30 AM

-- June 1, 2026 --

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York Globe Newswire 7:30 AM

-- April 30, 2026 --

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health Globe Newswire 7:17 PM
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference Globe Newswire 7:30 AM

-- April 28, 2026 --

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health Globe Newswire 7:30 AM

-- April 23, 2026 --

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan Globe Newswire 7:30 AM

-- April 20, 2026 --

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions Globe Newswire 8:15 AM
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer Globe Newswire 8:00 AM

-- April 16, 2026 --

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs Globe Newswire 7:30 AM

-- March 12, 2026 --

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer Globe Newswire 7:30 AM

-- March 5, 2026 --

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder Globe Newswire 7:30 AM

-- February 24, 2026 --

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee Globe Newswire 7:45 AM

-- February 17, 2026 --

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder Globe Newswire 7:30 AM

-- February 13, 2026 --

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights Globe Newswire 7:31 AM

-- February 10, 2026 --

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes